Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder)

Trelegy Ellipta is a prescription inhaler used to treat chronic obstructive pulmonary disease (COPD). Trelegy Ellipta combines three medicines to decrease the inflammation in the lungs and relax the muscles in the airways. Trelegy Ellipta should be used as a maintenance therapy and should not be used for sudden symptoms. Trelegy Ellipta is usually used in patients who are taking Breo Ellipta (fluticasone furoate and vilanterol) and need additional treatment, or those who are currently taking Incruse Ellipta (umeclidinium) and Breo.1,2

What are the ingredients in Trelegy Ellipta?

Trelegy Ellipta contains three active ingredients: fluticasone furoate, umeclidinium, and vilanterol. Fluticasone furoate is an inhaled corticosteroid. Umeclidinium is an anticholinergic, and vilanterol is a long-acting beta-agonist (LABA).1

How does Trelegy Ellipta work?

Each of the three ingredients in Trelegy Ellipta work in different ways to help treat the symptoms of COPD:

  • The inhaled corticosteroid, fluticasone furoate, helps reduce the inflammation in the lungs. Inflammation in the lungs can cause breathing problems in people with COPD.
  • The anticholinergic, umeclidinium, is a long-acting muscarinic antagonist (LAMA) and works by targeting the muscarinic receptors to relax the muscles in the airways.
  • The LABA, vilanterol, relaxes the muscles in the airways by targeting beta2-receptors.1

What are the possible side effects of Trelegy Ellipta?

The most common side effects experienced by patients taking Trelegy Ellipta in clinical trials are headache, back pain, diarrhea, cough, changes in taste, mouth, nose or throat pain, and inflammation of the intestines (gastroenteritis) which may cause flu-like symptoms.1

Trelegy Ellipta may also cause other side effects, including:

  • Increased risk of a yeast infection (candida albicans) of the mouth and throat, commonly known as thrush
  • Increased risk of pneumonia
  • Kidney damage1

The LABA medication in Trelegy Ellipta, vilanterol, may increase the risk of asthma-related death. The safety of Trelegy Ellipta for use in people with asthma has not be studied, and Trelegy Ellipta should not be used for the treatment of asthma.1,3

The corticosteroid medication in Trelegy Ellipta, fluticasone furoate, may increase the risk of worsening certain infections, such as existing tuberculosis (TB), fungal, bacterial, viral, or parasitic infections.1,3

Things to know about Trelegy Ellipta

Trelegy Ellipta should not be used as a rescue medication for sudden symptoms.1

Trelegy Ellipta should not be used by people with severe allergy to milk or any of the ingredients in Trelegy Ellipta.1

Trelegy Ellipta can increase the risk of developing a yeast infection of the mouth and throat. This risk can be reduced if the patient rinses his/her mouth without swallowing after using the inhaler.1,3

Before starting treatment with Trelegy Ellipta, patients should talk to their doctor about all medicines (over-the-counter and prescription), vitamins, and supplements they are taking. Some medications can interact with Trelegy Ellipta and may cause serious side effects. Trelegy Ellipta should not be used in combination with other LABA or anticholinergic medications.1

Before starting treatment with Trelegy Ellipta, patients should discuss all health conditions they have with their doctor, especially if they have any of the following:

  • Heart disease or heart problems
  • High blood pressure
  • Seizures
  • Thyroid problems
  • Diabetes
  • Liver problems
  • Osteoporosis
  • Immune system problems
  • Eye problems such as glaucoma or cataracts
  • Prostate or bladder problems
  • Allergies to milk proteins
  • Any type of viral, bacterial, parasitic, or fungal infection
  • Exposure to chickenpox or measles
  • Pregnancy, breastfeeding, or planning to become pregnant or breastfeed1

Dosing information

Trelegy Ellipta is to be used for inhalation by the mouth only. Trelegy Ellipta is inhaled once daily, and each inhalation contains 100 mcg fluticasone furoate, 62.5 mcg umeclidinium, and 25 mcg vilanterol.1

For more information, read the full prescribing information for Trelegy Ellipta.

Written by: Emily Downward | Last reviewed: April 2018.
View References
  1. Trelegy Ellipta prescribing information. Available at https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Trelegy/pdf/TRELEGY-PI-MG-IFU.PDF. Accessed 4/9/18.
  2. Trelegy product website for healthcare professionals. Available at https://www.gsksource.com/pharma/content/gsk/source/us/en/brands/trelegy/pi/home.html. Accessed 4/9/18.
  3. Trelegy Ellipta approved as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US. GSK press release. Available at https://www.gsk.com/en-gb/media/press-releases/trelegy-ellipta-approved-as-the-first-once-daily-single-inhaler-triple-therapy-for-the-treatment-of-appropriate-patients-with-copd-in-the-us/. Accessed 4/9/18.